BioSpace News Archive

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022.

Atrion Corporation. announced that its Board of Directors has approved a succession plan under which Cindy Ferguson, currently the Company’s Controller, will become the Company’s Vice President and Chief Financial Officer, Secretary, and Treasurer effective March 4, 2023, succeeding Jeffery Strickland, who currently holds those positions and whose retirement effective March 3, 2023 has been previously reported.

Statera Biopharma, Inc. announced that, as expected, the Company received an additional notice of non-compliance from the Listing Qualifications Staff of The Nasdaq Stock Market LLC due to the Company’s failure to timely file the Form 10-Q for the quarter ended June 30, 2022 with the Securities and Exchange Commission, as required by Nasdaq Listing Rule 5250.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or “Blueberries”), is pleased to report its financial results for the quarter ended on June 30, 2022.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that Dr. Kerry Blanchard has resigned as Chief Executive Officer and as a member of the Board of Directors, effective immediately.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, CEO and Executive Director of Aptorum Group will present both in-person and virtually at the H.C. Wainwright Global Investment Conference.

Shanghai Junshi Biosciences Co., Ltd announced that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology Co., Ltd., has received a notice from the U.S. Food and Drug Administration concerning the approval of the investigational new drug application for XPO1 inhibitor WJ01024 tablets by the FDA.